To read the full story, subscribe or sign in.

Inside the Beltway: Polis alone in arguing against a vote on IPAB, device tax repeal

June 18, 2015

By Mark McCarty

BioWorld MedTech

Today's news in brief

BioWorld

BioWorld briefs for May 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 13, 2025.

Little bite from voluntary most-favored nation Rx pricing order

BioWorld

After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

China’s NMPA gives thumbs up to Remegen’s ADC targeting HER2

BioWorld

China’s National Medical Products Administration has approved Remegen Co. Ltd.’s antibody-drug conjugate (ADC), disitamab vedotin (RC-48), for treatment of...